UNITAID Executive Board Meeting
25th Session
22-23 June 2016
Hôtel de Ville de Paris and
French Ministry of Foreign Affairs and
International Development
Paris, France

Resolution n° 7

Potential Opportunity: Malaria Vaccine

Acknowledging that the UNITAID Secretariat has received a proposal from WHO which sets out a potential opportunity for UNITAID to support a WHO-led pilot implementation programme for a malaria vaccine;

Acknowledging that the malaria vaccine opportunity does not fall within the scope of an existing Board approved Area for Intervention and therefore represents an exceptional case under UNITAID’s Operating Model, and having considered the context presented by the Secretariat during EB25;

The Executive Board recognizes the strategic fit of the malaria vaccine opportunity with UNITAID's mandate, whilst also acknowledging the significant risks associated with it.

The Executive Board therefore requests the Secretariat to maintain ongoing close collaboration with other potential co-funders/partners, and countries to conduct a full review of the proposal for the pilot implementation of the malaria vaccine in accordance with established processes under UNITAID's Operating Model. In particular, the proposal review should include a rigorous evaluation of the proposed budget, to ensure optimal value-for-money and to minimize certain cost categories, such as salaries and incentives, equipment and overheads.

The Executive Board notes that, in order to optimize strategic fit and minimize risks, a potential future Go-ahead of this proposal would be contingent upon:

- Co-financing for the pilot implementation programme across other key donors, such as Gavi and the Global Fund;
- WHO remaining in a leadership role, with full responsibility for technical design and implementation, communications and advocacy, and any potential liabilities linked to the project;
- WHO securing the total funding needed to fully finance Phase 1 of the pilot implementation programme;
- UNITAID funding limited to those activities with a clear fit with UNITAID's mandate and strategy – specifically research costs associated with Phase 1 of the pilot implementation programme, and excluding vaccine implementation costs;
- UNITAID funding shall be limited and proportionate, taking into account the degree of strategic fit.

The Executive Board's endorsement of strategic fit of the malaria vaccine opportunity has no budgetary implications.

Philipppe Douste-Blazy
Chair of the UNITAID Executive Board